Abstract
This chapter reviews the possible effectiveness of oral agents as an option for treatment of Peyronie’s disease (PD). We present the rationale for use of these drugs and base our recommendations on levels of published evidence and the report by the International Consultation on Urological Diseases. A definitive and ideal medical therapy for PD has yet to be established and will not be until we completely understand the trigger mechanism and the maintenance process of fibrosis in the tunica albuginea. Several oral substances have been proposed with promises of success; however, these agents appear to lack robust scientific support for their benefit. Until new evidence is available, the indications for oral treatment in PD are recent onset of disease, painful plaque, and unstable plaque. An early trial of inexpensive, safe, and well-tolerated oral therapy may be offered with limited enthusiasm for a positive outcome.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Mynderse LA, Monga M. Oral therapy for Peyronie’s disease. Int J Impot Res 2002; 14: 340–344.
Pryor JP, Akkus E, Alter G, et al. Priapism, Peyronie’ s disease and penile reconstructive surgery. In: Second International Consultation on Sexual Dysfunction—Paris, France (Lue TF, Basson R, Rosen R, et al., eds.). Health Publications, 2004, pp. 383–408.
Evidence-based medicine: overview of the main steps for developing and grading guideline recommendations. In: Second International Consultation on Sexual Dysfunction#x2014;Paris, France (Lue TF, Basson R, Rosen R, et al., eds.). Health Publications, 2004, pp. 15–16.
USP DI Drug Information for the Health Care Professional. Thomson Micromedex; Greenwood Village, CO, 2005.
Mosby’s Drug Consult. 15th ed. Mosby, St. Louis, MO, 2005.
Levine LA, Elterman L. Peyronie’s disease and its medical management. In: Male Infertility and Sexual Dysfunction (Hellstrom WJ, ed.). Springer-Verlag, New York, 1997, pp. 474–480.
Morgan RJ, Pryor JP. Procarbazine (Natulan) in the treatment of Peyronie’s disease. Br JUrol 1978; 50: 111.
AHFS Drug Information. American Society of Health-System Pharmacists, Bethesda, MD, 2005.
Scott W, Scardino P. A new concept in the treatment of Peyronie’s disease. South Med J 1948; 41: 173–176.
Pryor J, Farrel CR. Controlled clinical trial of vitamin E in Peyronie’ s disease. Prog Reprod Biol Med 1983; 9: 41–45.
Zarafonetis CJ, Horrax TM. Treatment of Peyronie’s disease with potassium para-aminobenzoate (Potaba). J Urol 1959; 81:770–772.
Hasche-Klunder, R. [Treatment of Peyronie’s disease with para-aminobenzoacidic potassium (POTABA) (author’s trans.)]. Urologe A 1978; 17: 224–227.
Shah, PJR, Green NA, Adib RS, et al. A multicentre double blind controlled clinical trial of potassium paraaminobenzoate (Potaba) in Peyronie’s disease. Prog Reprod Biol Med 1983; 9: 61–67.
Weidner W, Hauck EW, Schroeder-Printzen I, et al. Aminobenzoate potassium (Potaba) in the therapy of Peyronie’s disease. Int J Impot Res 2000 (suppl); 50.
Weidner W, Hauck EW, Schnitker J. Potassium paraaminobenzoate (Potaba) in the treatment of Peyronie’s disease: a prospective, placebo-controlled, randomized study. Eur Urol 2005; 47: 530–535.
Chau D, Mancoll JS, Lee S, et al. Tamoxifen downregulates TGF-#x03B2; production in keloid fibroblasts. Ann Plast Surg 1998; 40: 490–493.
Mikulec AA, Hanasono MM, Lum J, et al. Effect of tamoxifen on transforming growth factor #x03B2;1 production by keloid and fetal fibroblasts. Arch Facial Plast Surg 2001; 3: 111.
Ralph DJ, Brooks MD, Bottazzo GF, et al. The treatment of Peyronie’s disease with tamoxifen. Br J Urol 1992; 70: 648.
Teloken C, Rhoden EL, Grazziotin TM, et al. Tamoxifen vs placebo in the treatment of Peyronie’s disease. J Urol 1999; 162: 2003–2005.
Dominguez-Malagon HR, Alfeiran-Ruiz A, Chavarria-Xicotencatl P, et al. Clinical and cellular effects of colchicine in fibromatosis. Cancer 1992; 69: 2478–2483.
El-Sakka AI, Bakircioglu ME, Bhatnagar RS, et al. The effects of colchicine on a Peyronie’s-like condition in an animal model. J Urol 1999; 161: 1980–1983.
Akkus E, Carrier S, Rehman J, et al. Is colchicine effective in Peyronie’s disease? A pilot study. Urology 1994; 44: 291–295.
Erdogru T, Usta MF, Ates M, et al. Development of Peyronie’s disease during long-term colchicine treatment. Int Urol Nephrol 2003; 35: 207–208.
Kadioglu A, Tefekli A, Koksal T, et al. Treatment of Peyronie’s disease with oral colchicine: long-term results and predictive parameters of successful outcome. Int J Impot Res 2000; 12: 169–175.
Safarinejad MR. Therapeutic effects of colchicine in the management of Peyronie’s disease: a randomized double-blind, placebo-controlled study. Int J Impot Res 2004; 16: 238–243.
Prieto Castro RM, Leva Vallejo ME, Regueiro Lopez JC, et al. Combined treatment with vitamin E and colchicine in the early stages of Peyronie’s disease. BJU Int 2003; 91: 522–524.
Biagiotti G, Cavallini G. Acetyl-L-carnitine vs tamoxifen in the oral therapy of Peyronie’s disease: a preliminary report. BJU Int 2001; 88: 63–67.
Cavallini G, Biagiotti G, Koverech A, et al. Oral propionyl-L-carnitine and intraplaque verapamil in the therapy of advanced and resistant Peyronie’s disease. BJU Int 2002; 89: 895–900.
Chiao TB, Lee AJ. Role of pentoxifylline and vitamin E in attenuation of radiation-induced fibrosis. Ann Pharmacother 2005; 39: 516–522.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Humana Press Inc., Totowa, NJ
About this chapter
Cite this chapter
Teloken, C., Graziottin, T., Teloken, P.E. (2007). Oral Treatment of Peyronie’s Disease. In: Levine, L.A. (eds) Peyronie’S Disease. Current Clinical Urology. Humana Press. https://doi.org/10.1007/978-1-59745-161-1_6
Download citation
DOI: https://doi.org/10.1007/978-1-59745-161-1_6
Publisher Name: Humana Press
Print ISBN: 978-1-58829-614-6
Online ISBN: 978-1-59745-161-1
eBook Packages: MedicineMedicine (R0)